Samir SM, Abbas AM, Safwat SM, Elserougy HG
Aufgrund einseitiger Ernhrungsgewohnheiten nehmen viele Menschen jedoch bedeutend geringere Mengen auf
Newly released survey data revealed the following key trends for GLP-1 drug coverage: 60% of employers provide coverage for diabetes only (on the rise from 55% in 2025, 57% in 2024 and 49% in 2023) 36% provide coverage for both diabetes and weight loss (same as 2025, up from 34% in 2024 and 26% in 2023) 45% cover GLP-1 drugs for other FDA-approved conditions (sleep apnea, cardiovascular disease, etc.) Among employers not covering GLP-1 drugs for weight loss, 9% are considering adding coverage for weight loss
Our personalized programs are built on the foundation of responsible medical practice, ensuring that prescription GLP-1 medications are only offered to eligible individuals under strict medical supervision
Regardless of which option you lean toward, a prescription from a licensed medical doctor practicing within the USA is required